NYOH patients who need documentation to confirm eligibility to receive the COVID-19 vaccine, visit our COVID-19 resource page to learn how.
Learn More

Clinical Trials & Research

Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Disease Types: Solid Tumors,&nbs

Available at: {clinical_trial_location backspace="7"}Ph2 Pemigatinib Solids FGFR, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}